Gland Pharma Limited
Simbols: GLAND.NS
NSE
1688.1
INRTirgus cena šodien
42.3302
P/E koeficients
-1.6054
PEG koeficients
278.05B
MRK Cap
- 0.00%
DIV ienesīgums
Gland Pharma Limited (GLAND-NS) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 38362 | 32427.2 | 24465 | |||||||
balance-sheet.row.short-term-investments | 0 | 19273 | 29268.9 | 19546.8 | |||||||
balance-sheet.row.net-receivables | 0 | 8715.3 | 12514.7 | 12726.8 | |||||||
balance-sheet.row.inventory | 0 | 19453 | 11856.7 | 12751.7 | |||||||
balance-sheet.row.other-current-assets | 0 | 2477.8 | 1722.3 | 1292.9 | |||||||
balance-sheet.row.total-current-assets | 0 | 69008.1 | 58520.8 | 51236.4 | |||||||
balance-sheet.row.property-plant-equipment-net | 0 | 17361 | 17269 | 13244.4 | |||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.intangible-assets | 0 | 116.6 | 125.3 | 0 | |||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 116.6 | 125.3 | 0 | |||||||
balance-sheet.row.long-term-investments | 0 | -733.7 | 2000 | -19477.3 | |||||||
balance-sheet.row.tax-assets | 0 | 958.9 | -415.1 | 0 | |||||||
balance-sheet.row.other-non-current-assets | 0 | 1064.4 | 836.1 | 19957.3 | |||||||
balance-sheet.row.total-non-current-assets | 0 | 18767.3 | 19815.4 | 13724.4 | |||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-assets | 0 | 87775.4 | 78336.2 | 64960.8 | |||||||
balance-sheet.row.account-payables | 0 | 5873.5 | 4628.5 | 4007.3 | |||||||
balance-sheet.row.short-term-debt | 0 | 7.1 | 2.6 | 3 | |||||||
balance-sheet.row.tax-payables | 0 | 9.8 | 179.8 | 286.9 | |||||||
balance-sheet.row.long-term-debt-total | 0 | 37.4 | 44.8 | 47 | |||||||
Deferred Revenue Non Current | 0 | 49.9 | 55.5 | 56.7 | |||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||
balance-sheet.row.other-current-liab | 0 | 924.7 | 552.6 | 63.3 | |||||||
balance-sheet.row.total-non-current-liabilities | 0 | 896.8 | 939.8 | 803.1 | |||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.capital-lease-obligations | 0 | 6.3 | 8.1 | 9.3 | |||||||
balance-sheet.row.total-liab | 0 | 8188.1 | 6760 | 5928.4 | |||||||
balance-sheet.row.preferred-stock | 0 | 15.6 | 0 | 0 | |||||||
balance-sheet.row.common-stock | 0 | 164.7 | 164.3 | 163.6 | |||||||
balance-sheet.row.retained-earnings | 0 | 60153.9 | 52343.4 | 40226.8 | |||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -15.6 | 114.5 | 240.9 | |||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 19268.6 | 18953.9 | 18401.1 | |||||||
balance-sheet.row.total-stockholders-equity | 0 | 79587.2 | 71576.2 | 59032.4 | |||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 87775.4 | 78336.2 | 64960.8 | |||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||
balance-sheet.row.total-equity | 0 | 79587.2 | 71576.2 | 59032.4 | |||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||
Total Investments | 0 | 18539.3 | 2000 | 69.5 | |||||||
balance-sheet.row.total-debt | 0 | 44.5 | 47.4 | 50 | |||||||
balance-sheet.row.net-debt | 0 | -19044.4 | -3110.8 | -4868.3 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 10545.8 | 16185.5 | 13348.1 | |||||||
cash-flows.row.depreciation-and-amortization | 0 | 1467.4 | 1103 | 987.8 | |||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -4143.8 | -3254 | |||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 46.2 | 155.3 | |||||||
cash-flows.row.change-in-working-capital | 0 | -4179.4 | -3930.8 | -4357.6 | |||||||
cash-flows.row.account-receivables | 0 | 1440 | -4195.7 | -602 | |||||||
cash-flows.row.inventory | 0 | -7596.3 | 895 | -5188.9 | |||||||
cash-flows.row.account-payables | 0 | 1209.8 | 658.5 | 1428.2 | |||||||
cash-flows.row.other-working-capital | 0 | 767.2 | -1288.6 | 5.1 | |||||||
cash-flows.row.other-non-cash-items | 0 | -4194.1 | -1352.4 | -830.4 | |||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -2231.2 | -5221.2 | -2287.8 | |||||||
cash-flows.row.acquisitions-net | 0 | -12705.6 | 6117.2 | 4.3 | |||||||
cash-flows.row.purchases-of-investments | 0 | -4699.8 | -16818.1 | -13575.9 | |||||||
cash-flows.row.sales-maturities-of-investments | 0 | 17405.4 | 10700.9 | -4.3 | |||||||
cash-flows.row.other-investing-activites | 0 | 14313.1 | -4805 | 623.7 | |||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 12081.9 | -10026.2 | -15240 | |||||||
cash-flows.row.debt-repayment | 0 | -1.1 | -1.4 | -8.9 | |||||||
cash-flows.row.common-stock-issued | 0 | 215 | 385.5 | 12418.1 | |||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||
cash-flows.row.other-financing-activites | 0 | -64.7 | -35.2 | -24.6 | |||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 149.2 | 349 | 12384.6 | |||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 30 | 33.1 | 35.8 | |||||||
cash-flows.row.net-change-in-cash | 0 | 15900.8 | -1736.4 | 3229.7 | |||||||
cash-flows.row.cash-at-end-of-period | 0 | 19089 | 3188.2 | 4924.6 | |||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3188.2 | 4924.6 | 1695 | |||||||
cash-flows.row.operating-cash-flow | 0 | 3639.7 | 7907.7 | 6049.3 | |||||||
cash-flows.row.capital-expenditure | 0 | -2231.2 | -5221.2 | -2287.8 | |||||||
cash-flows.row.free-cash-flow | 0 | 1408.5 | 2686.5 | 3761.5 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 36246 | 43841.4 | 34236.4 | |||||||
income-statement-row.row.cost-of-revenue | 0 | 16854.3 | 21092.2 | 14918.7 | |||||||
income-statement-row.row.gross-profit | 0 | 19391.7 | 22749.3 | 19317.6 | |||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.other-expenses | 0 | 2404.6 | 16 | 82.8 | |||||||
income-statement-row.row.operating-expenses | 0 | 10611.5 | 8745.5 | 7280.4 | |||||||
income-statement-row.row.cost-and-expenses | 0 | 27465.7 | 29837.7 | 22199.2 | |||||||
income-statement-row.row.interest-income | 0 | 1794.2 | 1386.5 | 859.5 | |||||||
income-statement-row.row.interest-expense | 0 | 74.5 | 34 | 29.1 | |||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||
income-statement-row.row.total-other-income-expensenet | 0 | 1701.4 | 2185.2 | 1313.7 | |||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||
income-statement-row.row.other-operating-expenses | 0 | 2404.6 | 16 | 82.8 | |||||||
income-statement-row.row.total-operating-expenses | 0 | 1701.4 | 2185.2 | 1313.7 | |||||||
income-statement-row.row.interest-expense | 0 | 74.5 | 34 | 29.1 | |||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1467.4 | 1103 | 987.8 | |||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||
income-statement-row.row.operating-income | 0 | 8844.4 | 14000.3 | 12034.5 | |||||||
income-statement-row.row.income-before-tax | 0 | 10545.8 | 16185.5 | 13348.1 | |||||||
income-statement-row.row.income-tax-expense | 0 | 2735.4 | 4068.9 | 3378.5 | |||||||
income-statement-row.row.net-income | 0 | 7810.4 | 12116.6 | 9969.6 |
Biežāk uzdotie jautājumi
Kas ir Gland Pharma Limited (GLAND.NS) kopējie aktīvi?
Gland Pharma Limited (GLAND.NS) kopējie aktīvi ir 87775350000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.605.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir 35.155.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 0.134.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 0.189.
Kāda ir Gland Pharma Limited (GLAND.NS) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir 7810430000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 44530000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 10611470000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.